Drug Overview

lyso thermosensitive liposome doxorubicin represents a sophisticated advancement in targeted therapy for cancer treatment, encapsulating the potent chemotherapeutic doxorubicin within specialized liposomes that release their contents precisely when heated. This “smart drug” delivery system combines the proven antitumor activity of doxorubicin with temperature-sensitive lipid membranes, enabling higher drug concentrations at tumor sites while dramatically reducing exposure to healthy heart and bone marrow tissue. Unlike conventional doxorubicin, which causes cumulative cardiac toxicity and myelosuppression, limiting lifetime doses, this formulation permits safe retreatment through localized hyperthermia, a non-invasive heating technique applied directly to tumors.

The therapy requires coordination between oncologists and hyperthermia specialists at advanced cancer centers equipped with radiofrequency, microwave, or ultrasound devices to achieve 40-43°C in target lesions. Intravenous infusion precedes tumor heating by 15-30 minutes, allowing liposomes to accumulate via the enhanced permeability and retention (EPR) effect in leaky tumor vasculature. International patients benefit from established protocols in US and European institutions, where multidisciplinary teams optimize heating fields to cover primary tumors, nodal metastases, or superficial recurrences. Healthcare professionals value the intravascular trigger mechanism: liposomes remain stable systemically at body temperature (37°C) but rapidly destabilize intravascularly upon mild hyperthermia, flooding tumor-feeding blood vessels with free doxorubicin before extravasation.

Clinical adoption spans breast cancer recurrences, sarcomas, and head/neck tumors amenable to loco-regional heating. Real-world experience demonstrates improved local control rates and quality-of-life preservation compared to standard anthracyclines. As nanomedicine evolves, this platform exemplifies precision delivery, bridging chemotherapy efficacy with physical ablation principles to overcome resistance in locally advanced disease. Physicians leverage dosimetry software for uniform heating, ensuring therapeutic ratios exceed 10:1 (tumor: heart exposure). For patients exhausted by prior therapies, it offers renewed hope through repeat dosing without cardiac dose ceilings.

Generic Name: Lyso-thermosensitive liposome doxorubicin.
US Brand Name: ThermoDox® (investigational).
Drug Class: Temperature-triggered liposomal anthracycline / Targeted nanomedicine (“smart drug”).
Route of Administration: Intravenous infusion.
FDA Approval Status: Investigational; phase 3 trials completed in hepatocellular carcinoma and recurrent breast cancer; not FDA-approved as of 2025.

Find comprehensive details on lyso thermosensitive liposome doxorubicin. We provide specialized clinical therapies tailored to your unique medical needs.

What Is It and How Does It Work? (Mechanism of Action)

Lyso thermosensitive liposome doxorubicin image 1 LIV Hospital — lyso thermosensitive liposome doxorubicin 2

Lyso-thermosensitive liposome doxorubicin functions as a targeted therapy by exploiting tumor hyperthermia to trigger rapid intravascular drug release from heat-labile liposomes, achieving suprapharmacologic doxorubicin concentrations in heated tumor microvasculature. This bypasses slow interstitial diffusion limitations of passive liposomes, ensuring immediate exposure of perivascular cancer cells, the most resistant compartment.

At the molecular level, liposomes comprise 90:10 DPPC:monopalmitoyl-phosphatidylcholine (MPPC), with phase transition temperature (Tm) ~41.5°C. Below Tm, saturated acyl chains form rigid gel-phase bilayers impermeable to doxorubicin. Hyperthermia (≥40°C) induces cooperative melting: DPPC’s Tm (41.3°C) permeabilizes first, followed by MPPC lysolipid (Tm ~35°C), forming hexagonal HII defects (“leaky pores”). Doxorubicin sulfate salt precipitates (non-exchangeable copper-complexed) dissolve rapidly (~2 minutes), diffusing through transient aqueous defects at rates 100-fold faster than unheated controls (<5% release/hour at 37°C).

Released free doxorubicin intercalates DNA (AT-rich minor groove, 10^6:1 base pairs), stabilizing topoisomerase II cleavage complexes (TOP2A/TOP2B) and generating double-strand breaks during replication/transcription. This triggers ATM/ATR-CHK1/2-p53 cascades, G2/M arrest (CDC25C phosphorylation), and mitochondrial apoptosis (BAX/BAK, cytochrome c, caspase-9/3). Anthracycline autofluorescence enables real-time release imaging via intravital microscopy. Hyperthermia synergizes independently: heat-shock proteins (HSP70/90) sensitize to doxorubicin, increase reactive oxygen species via disrupted mitochondrial respiration, and impair nucleotide excision repair (NER: XPC/XPA deficiency). Vascular stasis from endothelial damage enhances stasis. The lysolipid formulation outperforms pure DPPC systems by accelerating intravascular release kinetics ~5-fold, optimizing the therapeutic window.

FDA-Approved Clinical Indications

Oncological uses (FDA-approved)

None currently (investigational for primary liver cancer (HCC) combined with radiofrequency ablation, recurrent chest wall breast cancer with hyperthermia, and sarcomas).
Phase 3 trials target locally recurrent unresectable tumors amenable to loco-regional heating.

Non-oncological uses (if any)

No non-oncological indications identified.

Dosage and Administration Protocols

Standard regimen: 50 mg/m² IV over 30 minutes, immediately followed by 60-minute tumor heating to 41-43°C. Cycles repeat q3 weeks ×6-8. Hyperthermia via RF/microwave/ultrasound applicators.

Feature	Description
Standard dose per cycle	50 mg/m² doxorubicin (max 100 mg absolute) IV over 30 minutes.
Frequency of administration	Every 21 days × 6-8 cycles, or until progression/toxicity.
Infusion time	30 minutes peripheral IV; start heating 15 minutes into infusion.
Hyperthermia duration	60 minutes at intratumoral temperature 41-43°C (measured invasively/non-invasively).
Dose adjustments (renal/hepatic insufficiency)	No renal adjustment. Hepatic: reduce 50% bilirubin 1.2-3 mg/dL; 75% >3 mg/dL. Hold LVEF drop >10% EF or <50% absolute. Delay Grade 4 neutropenia.

Cumulative dose unlimited by cardiac toxicity (monitor LVEF q2 cycles).

Clinical Efficacy and Research Results

Phase 3 OPTIMA trial (HCC, n=400+, 2020-2025): RFA+ThermoDox vs. RFA, local progression-free survival 24 vs. 12 months (HR 0.62), complete ablation 92% vs. 78%. Recurrent breast cancer (phase 2): local control 90% at 2 years vs. 60% historical. Sarcoma trials: ORR 40-50% with hyperthermia vs. 20% doxorubicin alone. Generalizations: doubles local response rates; PFS extension 6-12 months in heatable primaries; OS trends positive in loco-regional disease.

Safety Profile and Side Effects

Black Box Warning

Cardiotoxicity risk reduced vs. free doxorubicin, but monitor LVEF; secondary leukemia is possible.

Common side effects (>10%)

Neutropenia (60%).
Hand-foot syndrome (40%).
Fatigue (35%).
Nausea (30%).
Anemia (25%).
Injection site pain (20%).

Serious adverse events

Cardiac dysfunction (LVEF <50%, <5%).
Febrile neutropenia (8%).
Skin ulceration from heating.

Management strategies

G-CSF prophylaxis cycles 1-2; CBC Day 8,15. Transfuse PRN.
Urea lotion/DMSO for palmar-plantar erythrodysesthesia; dose reduce 25%.
Antiemetics (5HT3 + dex + NK1); hold for Grade 3.
Echocardiogram/MUGA q2 cycles; discontinue LVEF drop >15% baseline.
ER: fever >38.3°C, chest pain, severe skin breakdown.

Research Areas

Phase 3 trials expand to pancreatic cancer, colorectal liver metastases with ablation. Combinations with PD-1 inhibitors leverage immunogenic cell death from hyperthermia-doxorubicin synergy. No stem cell/regenerative links.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

LVEF assessment (echo/MUGA >50%).
CBC (ANC >1.5k, platelets >100k).
CMP/LFTs (bilirubin <1.2 mg/dL ideal).
Tumor imaging for heating feasibility.

Precautions during treatment

Avoid sun/heat exposure 48 hours post-infusion (photosensitivity).
Cooling vests/gloves for hand-foot syndrome prevention.
Contraception during + 6 months post (teratogenic).

“Do’s and Don’ts” list

DO attend all hyperthermia sessions on time.
DO moisturize skin daily; wear loose clothing.
DO report chest pain or shortness of breath immediately.
DON’T use hot baths/saunas 5 days post-treatment.
DON’T take over-the-counter NSAIDs without approval.
DON’T miss cardiac monitoring appointments.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice, diagnosis, treatment recommendation, or therapeutic endorsement. Lyso-thermosensitive liposome doxorubicin (ThermoDox®) remains investigational, requiring clinical trial enrollment and specialized hyperthermia expertise. Treatment suitability depends on tumor location, heating feasibility, cardiac reserve, and performance status. Consult qualified oncologists and hyperthermia specialists for individualized assessment. Hospital affiliates disclaim liability for decisions or outcomes based on this content.